Sona Nanotech Inc. (SNANF)
OTCQB OTCQB Primary Summary
Sona Nanotech CEO on breakthrough cancer therapy results - ICYMI
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has reported promising first-in-human results for its targeted hyperthermia therapy (THT), showing tumor elimination in most treated patients with advanced melanoma who had stopped responding to standard immunotherapy. The findings mark a major milestone for the Halifax-based nanotechnology company as it transitions from preclinical research to clinical development.
Sona Nanotech poised for clinical breakthrough after melanoma study
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) is stepping into clinical-stage biotech after reporting promising results from its first-in-human trial of Targeted Hyperthermia Therapy (THT) for advanced melanoma. The early feasibility study treated 10 patients whose melanoma had not responded to standard immunotherapies.
Sona Nanotech reveals positive response rate in first-in-human THT cancer therapy study
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) Inc announced that it has completed its first-in-human clinical study treating patients with histologically confirmed, immunotherapy-resistant cutaneous metastatic melanoma using Sona's Targeted Hyperthermia Therapy. The company said by day 15, eight of 10 patients experienced a significant clinical response to treatment with a majority (six out of eight) showing no detectable residual melanoma in representative, biopsied tumors, and two patients showing no response.
Sona Nanotech Inc. (SNANF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sona Nanotech Inc. ever had a stock split?
Sona Nanotech Inc. Profile
| Professional Services Industry | Industrials Sector | Mr. David Andrew Regan CEO | OTCQB Exchange | CA83541C1059 ISIN |
| Canada Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Sona Nanotech Inc. is a pioneering nanotechnology life sciences firm established in 2013 and headquartering in Halifax, Canada. The company is at the forefront of developing innovative therapeutic and diagnostic solutions primarily in the cancer treatment sector and in other critical healthcare diagnostics. Utilizing nanotechnology, Sona Nanotech Inc. focuses on creating highly specific treatments and rapid diagnostic tools, aiming to improve patient outcomes and provide faster, more accurate health insights.
Products and Services
- Targeted Hyperthermia Therapy for Cancer Treatment
A novel approach by Sona Nanotech which uses heat generated from nanoparticles to treat cancer by targeting only cancerous cells, leaving the healthy cells unharmed. This therapy is being developed to provide a less invasive option than traditional treatments, with the hope of reducing side effects and improving recovery times.
- Nanomedical Therapy for the Treatment of Colorectal Cancer
This innovative treatment method focuses on colorectal cancer by using nanotechnology to deliver medicines more effectively to the cancer cells. Sona Nanotech’s strategy enhances the drug's impact on the targeted cancer cells while minimizing the distribution of the drug to non-cancerous cells, potentially lessening the side effects commonly associated with cancer treatments.
- Gold Nanoparticle Products
Specializing in the production of gold nanoparticles, Sona Nanotech Inc. leverages these particles' unique properties for various applications, including medical imaging and as carriers for drug delivery. The gold nanoparticles can be used to improve the precision and effectiveness of diagnostic and therapeutic practices.
- Lateral Flow Assay Rapid Tests
The company designs rapid diagnostic tests based on the lateral flow assay technology. These tests offer quick, reliable results for various applications, including but not limited to, infectious disease detection, environmental testing, and food safety. The portability and ease of use make these tests an essential tool for rapid decision-making in healthcare and beyond.
- Bovine TB Tests
Addressing the critical need for early detection of tuberculosis in cattle, Sona Nanotech has developed a specific diagnostic test for Bovine TB. Early detection is crucial to prevent the spread of the disease, ensuring the health of cattle and reducing the potential risk to humans.
- Concussion Screening Tests
Expanding their reach beyond infectious diseases and cancer, Sona Nanotech is also developing rapid screening tests for concussions. These tests are designed to be administered immediately after an injury occurs, providing quick information about the potential severity of a concussion and aiding in the decision-making process for further medical care.
Contact Information
